Molecular Innovations Assay Cited in Groundbreaking Research Paper

 

Link to New York Times article:

Amish Mutation Protects Against Diabetes and May Extend Life

 

Link to Science Advances article:

A null mutation in SERPINE1 protects against biological aging in humans

 

Abstract

Plasminogen activator inhibitor–1 (PAI-1) has been shown to be a key component of the senescence-related secretome and a direct mediator of cellular senescence. In murine models of accelerated aging, genetic deficiency and targeted inhibition of PAI-1 protect against aging-like pathology and prolong life span. However, the role of PAI-1 in human longevity remains unclear. We hypothesized that a rare loss-of-function mutation in SERPINE1 (c.699_700dupTA), which encodes PAI-1, could play a role in longevity and metabolism in humans. We studied 177 members of the Berne Amish community, which included 43 carriers of the null SERPINE1 mutation. Heterozygosity was associated with significantly longer leukocyte telomere length, lower fasting insulin levels, and lower prevalence of diabetes mellitus. In the extended Amish kindred, carriers of the null SERPINE1 allele had a longer life span. Our study indicates a causal effect of PAI-1 on human longevity, which may be mediated by alterations in metabolism. Our findings demonstrate the utility of studying loss-of-function mutations in populations with geographic and genetic isolation and shed light on a novel therapeutic target for aging.

“Plasma samples preserved in citrate were assayed for human PAI-1 total antigen with the Molecular Innovations PAI-1 ELISA…The intra-assay CV was 6.15%, and the inter-assay CV was 5.98%.”

 

Links to related products:

Human PAI-1 total antigen assay ELISA kit

Active human PAI-1 functional assay ELISA kit

Active Human PAI-1 Functional Assay ELISA Kit for Non Plasma Samples

PAI-1 Knockout Mice

PAI-1 Proteins

PAI-1 Monoclonal Antibodies

PAI-1 Polyclonal Antibodies